Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, announced that six of its abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2024, taking place from June 5-8 in Milan, Italy. The accepted abstracts include findings on their novel therapeutics for liver and viral diseases.
Highlighted abstracts involve the Capsid Assembly Modulator (CAM) ALG-000184, which has shown promising antiviral effects in chronic hepatitis B (CHB) patients. Notably, two abstracts have earned 'Top' recognition for their outstanding contribution: one on second-generation HBV siRNAs demonstrating improved profiles, and another on CAM-A molecules inducing rapid HBsAg reductions in animal models.
The presentations cover both preclinical and clinical research, reflecting Aligos' leadership in addressing unmet medical needs in liver diseases.
- Six abstracts accepted for presentation at EASL 2024.
- Two abstracts received 'Top' recognition for their outstanding contributions.
- Promising results from CAM-E ALG-000184 in reducing viral markers in CHB patients.
- Preclinical research on second-generation HBV siRNAs shows improved profiles.
- CAM-A molecules ALG-006746 and ALG-006780 demonstrate rapid HBsAg reductions in animal models.
- No immediate financial impact reported from the accepted presentations.
- data on long-term efficacy and safety of the therapeutics presented.
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The abstracts released today can be found on the EASL website at www.easlcongress.eu.
Details from the abstracts released today are as follows:
ALG-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB)
Abstract #: 603
Title: Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAb trends
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Abstract #: 895
Title: Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels
Presenter: Kosh Agarwal, MBBS, MRCP (UK), MD, FRCP (Ed), FRCP (London), Consultant Hepatologist and Transplant Physician, Institute of liver Studies, King’s College Hospital NHS Foundation Trust
Abstract #: 2390
Title: Association of baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment
Presenter: Kha Le, PhD
Preclinical
Abstract #: 1298
Title: In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Presenter: Jieun Song, PhD
Abstract #: 1338 (Top)
Title: Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
Presenter: Jin Hong, PhD
Abstract #: 1763 (Top)
Title: Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Presenter: Yannick Debing, PhD
Abstracts identified as “Top” were selected as among the best in their category. These posters will be displayed during the four days of the congress.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
What are the key highlights of Aligos Therapeutics' presentations at EASL 2024?
When and where is the EASL Congress 2024 taking place?
What is ALG-000184?
What are the promising findings related to ALG-000184?
What recognition did Aligos Therapeutics receive for their research at EASL 2024?
